🟢 RLAY is trading 4.4% up today extending momentum from recent clinical data

RLAY is trading at $19.73 (4.4% up), extending its multi-day rebound as momentum continues from prior positive clinical data on zovegalisib.

• The stock is climbing despite no fresh company-specific headlines or filings on July 7, 2026.
• Supportive analyst sentiment continues to bolster the move, allowing the stock to outperform a broadly weaker market backdrop.